Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors.

Palm, Christiane; Connolly, Catherine E; Masser, Regina; Padberg Sgier, Barbara; Karamitopoulou, Eva; Simon, Quentin; Bode, Beata; Tinguely, Marianne

Palm, Christiane; Connolly, Catherine E; Masser, Regina; Padberg Sgier, Barbara; Karamitopoulou, Eva; Simon, Quentin; Bode, Beata; Tinguely, Marianne.

Afiliación

Palm C; Pathologie Institute Enge, 8005 Zurich, Switzerland.
Connolly CE; Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland.
Masser R; Pathologie Institute Enge, 8005 Zurich, Switzerland.
Padberg Sgier B; Pathologie Institute Enge, 8005 Zurich, Switzerland.
Karamitopoulou E; Pathologie Institute Enge, 8005 Zurich, Switzerland.
Simon Q; Pathologie Institute Enge, 8005 Zurich, Switzerland.
Bode B; Pathologie Institute Enge, 8005 Zurich, Switzerland.
Tinguely M; Pathologie Institute Enge, 8005 Zurich, Switzerland.

Diagnostics (Basel) ; 13(1)2023 Jan 03.

Article en En | MEDLINE | ID: mdl-36611460

Palabras clave

HER2 immunohistochemistry; HER2 in situ hybridization; artificial intelligence; breast carcinoma; digital pathology

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: Diagnostics (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google